Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Dr Mark Wildgust: Updated APOLLO Trial Results Confirm Daratumumab Safety in Multiple Myeloma
Adding daratumumab to standard-of-care regimens consistently improves outcomes among patients with multiple myeloma, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
HIV Remains a Top-10 Cause of Death for Some Populations, Despite Overall Mortality Drops
The most recent data from the CDC show a 36.6% decrease in overall mortality among individuals living with HIV; despite this progress, the virus remains a leading cause of death among certain races and ethnicities.
Steady Increase Seen in Cardiac Arrest−Related Overdoses During COVID-19 Pandemic
Overdose-related cardiac arrests rose consistently in the first few months of the coronavirus disease 2019 (COVID-19) pandemic, coming in at 48.5% above baseline through August 1, according to national emergency medical services data.
Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy
Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Sacubitril/Valsartan Treatment for HFrEF Results in Removal of Prior Authorization Requirement
Study results demonstrate the multimillion-dollar savings achieved among patients with heart failure with reduced ejection fraction (HFrEF) following treatment initiation with sacubitril and valsartan.